Skip to main content
Smart Investors Daily
Vertex Pharmaceuticals Incorporated logo

NASDAQ · VRTX

Vertex Pharmaceuticals Incorporated

Healthcare · Biotechnology

$536.45

Down-$15.79 (-2.94%)

Updated Nov 20, 2026, 1:18 AM

SID Score

6.6/10

Composite research score

Smart Money

48/100

Neutral

Market cap
114.46B
P/E ratio
31.02
Dividend yield
0.00%
52-week range
$412.27 – $568.67
Volume
1.29M
Avg. volume
1.51M

Price performance · VRTX

VRTX price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 18, 2026

VRTX closed at $536.45 after 20 trading sessions, up 0.24% for the selected period.

Last close
$536.45
Period change
+0.24%
Period low
$517.49
Period high
$558.88
Daily close
View OHLC price history
VRTX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 18, 2026$532.27$542.76$531.38$536.451.29M
Nov 17, 2026$532.76$538.56$529.00$534.201.51M
Nov 16, 2026$547.86$549.56$534.1175$537.791.22M
Nov 13, 2026$542.12$543.73$536.12$538.60756.2K
Nov 12, 2026$547.87$552.27$542.51$542.62984.59K
Nov 11, 2026$543.96$548.67$535.46$547.031.08M
Nov 10, 2026$546.965$551.86$543.44$547.891.24M
Nov 9, 2026$555.99$555.99$538.4802$550.871.21M
Nov 6, 2026$531.53$548.76$531.53$547.091.27M
Nov 5, 2026$556.85$557.85$540.015$542.502.48M
Nov 4, 2026$535.63$550.77$527.38$549.041.83M
Nov 3, 2026$558.44$561.96$529.1501$530.762.37M
Nov 2, 2026$560.875$568.6699$544.0929$553.153.21M
Oct 30, 2026$550.73$563.7995$549.89$558.883.03M
Oct 29, 2026$536.46$546.61$534.01$540.001.54M
Oct 28, 2026$514.45$534.94$513.37$529.691.28M
Oct 27, 2026$514.835$521.43$509.205$521.031.02M
Oct 26, 2026$526.86$529.66$509.33$517.491.19M
Oct 23, 2026$531.66$533.08$522.91$523.93832.63K
Oct 22, 2026$527.18$537.81$521.295$535.171.64M

Latest VRTX news

The latest Smart Investors Daily articles mentioning VRTX.

VRTX research

Overview

Company profile and research snapshot.

Company profile

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$483.00
Implied upside
—
Analysts
24
VRTX recent ratings
DateFirmRatingTarget
Nov 4, 2026BarclaysOverweight—
Nov 3, 2026StifelHold—
Nov 3, 2026Cantor FitzgeraldOverweight—
Nov 3, 2026RBC CapitalOutperform—
Nov 3, 2026Wells FargoOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 12, 2026

Vertex Resource Group Ltd. Reports Third Quarter 2026 Results

(TSXV: VTX) - Vertex Resource Group Ltd. ("Vertex" or the "Company") reports its financial and operational results for the third quarter ended September 30, 2026. The following should be read in conjunction with the Management Discussion and Analysis ("MD&A") and the unaudited condensed consolidated interim financial statements of Vertex for the period ended September 30, 2026, which are available on SEDAR+ at www.sedarplus.ca.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.